Somewhat Critical Press Coverage Somewhat Unlikely to Impact DURECT Corporation (DRRX) Stock Price

Press coverage about DURECT Corporation (NASDAQ:DRRX) has trended somewhat negative on Tuesday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DURECT Corporation earned a news impact score of -0.01 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.6837210875192 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

DURECT Corporation (DRRX) traded up 1.6446% during midday trading on Tuesday, reaching $0.7973. The company’s stock had a trading volume of 800,061 shares. The firm’s market cap is $117.20 million. DURECT Corporation has a 52-week low of $0.74 and a 52-week high of $2.17. The firm has a 50 day moving average of $1.62 and a 200 day moving average of $1.46.

DURECT Corporation (NASDAQ:DRRX) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.02). The firm had revenue of $4.32 million during the quarter, compared to analyst estimates of $5.17 million. DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. Analysts anticipate that DURECT Corporation will post ($0.24) earnings per share for the current fiscal year.

Several brokerages recently issued reports on DRRX. ValuEngine upgraded DURECT Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. HC Wainwright cut DURECT Corporation from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Friday, October 20th. Stifel Nicolaus cut DURECT Corporation from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. Finally, Laidlaw cut their target price on DURECT Corporation from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, October 20th.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT Corporation (NASDAQ:DRRX)

What are top analysts saying about DURECT Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DURECT Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit